Gyre Therapeutics Inc (GYRE)

Gyre Therapeutics' stock price has declined in the past six months. The share price decreased by 36.61% between November 18, 2024, and November 17, 2025, and has fallen by 23.44% over the last six months and 5.75% in the past month as of November 24, 2025. Key events impacting the stock include the Third Quarter 2025 financial results and business update, completion of patient enrollment in a Phase 3 clinical trial of Pirfenidone Capsules for Pneumoconiosis, presentation of positive Phase 3 clinical trial results for Hydronidone in chronic Hepatitis B, being dropped from the Russell 3000 Value Index, and a proposed underwritten offering.

There is no direct information available regarding demand seasonality for Gyre Therapeutics' products and services. Fluctuations in the Chinese economy and decreasing healthcare spending impacted ETUARY and generic drug sales volumes in 2024, but this is not explicitly described as seasonality. Data on stock performance seasonality does not reflect product demand seasonality.

Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs within the Healthcare sector. The company's primary focus is on organ fibrosis and inflammatory diseases. Its major products and pipeline candidates include Hydronidone (F351) for MASH-associated liver fibrosis and CHB-associated liver fibrosis, ETUARY (Pirfenidone) for IPF and other fibrotic conditions, Avatrombopag for thrombocytopenia, Nintedanib for fibrosing interstitial lung disease, F573 for acute-on-chronic liver failure, F528 for chronic obstructive pulmonary disease, and F230 for pulmonary arterial hypertension.

Gyre Therapeutics is headquartered in San Diego, California, USA, and operates in both the United States and China. The company advances a diverse pipeline in China through a controlling interest in Beijing Continent, also referred to as Gyre Pharmaceuticals.

Gyre Therapeutics has generally received "Very Positive News" and "Positive News" sentiment ratings from MarketBeat in the past year. Wall Street analysts have a "Hold" consensus rating for GYRE shares, with an average price target of $17.00, suggesting a potential upside of 116.56% from the current price. There have been no specific events identified that have negatively impacted Gyre Therapeutics' brand reputation in the past year, beyond the general stock price decline.

GNI Group Ltd. is the largest individual shareholder of Gyre Therapeutics, Inc., owning between 72.95% and 73% of the company's shares. Major institutional owners and shareholders include Vanguard Group Inc., BlackRock, Inc., Geode Capital Management, LLC, State Street Corp., SBI Securities Co., Ltd., Charles Schwab Investment Management Inc., Northern Trust Corp., and Millennium Management LLC. As of September 2025, 132 institutional owners and shareholders held a total of 3,749,481 shares, representing 23.99% of the stock.